Aurinia Pharmaceuticals (AUPH) AI Stock Analysis

• Market Cap: $1.60B
• Dividend Yield: N/A
• Average Volume (3M): 1.55M
• Price to Earnings (P/E): 28.3
• Beta (1Y): 0.69
• Revenue Growth: 25.59%
• EPS Growth: N/A
• Country: US
• Employees: 130
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 131,629,550
• 10 Day Avg. Volume: 1,080,974
• 30 Day Avg. Volume: 1,553,148
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $11.00
• Price Target Upside: -16.48% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 79 Outperform
• Price Target: $15.00 ▲(13.90% Upside)

Aurinia Pharmaceuticals demonstrates strong financial performance and positive earnings call highlights, contributing to a favorable outlook. However, the stock's high valuation and technical indicators suggest caution. The absence of corporate events further consolidates the focus on financial and earnings performance.

Positive Factors

Revenue Growth

Aurinia's consistent revenue growth indicates strong market demand for LUPKYNIS, enhancing its competitive position in the kidney disease treatment market.

Cash Flow Management

Positive cash flow from operations reflects effective cash management and operational efficiency, supporting long-term financial stability.

Clinical Development

Successful clinical trials for new compounds like aritinercept can expand Aurinia's product pipeline, driving future growth and innovation.

Negative Factors

Cash and Investments Decrease

A decrease in cash and investments could limit Aurinia's ability to fund future growth initiatives or respond to unexpected financial challenges.

Share Repurchase Impact

Significant share repurchases may strain cash reserves, potentially impacting liquidity and limiting investment in growth opportunities.

Profitability Challenges

Historical profitability challenges suggest potential risks in maintaining current margins, which could affect long-term financial performance.

Aurinia Pharmaceuticals Business Overview & Revenue Model

Company Description

Aurinia Pharmaceuticals Inc. is a biotechnology company focused on developing and commercializing innovative therapies for kidney diseases, particularly lupus nephritis. The company is primarily engaged in the research and development of its lead product, LUPKYNIS (voclosporin), which is designed to improve renal response in patients with this autoimmune condition. Based in Victoria, British Columbia, Aurinia operates in the biopharmaceutical sector, leveraging its expertise in immunology and nephrology to address significant unmet medical needs.

How the Company Makes Money

Aurinia Pharmaceuticals generates revenue primarily through the sale of its commercialized product, LUPKYNIS, which was approved by the FDA for the treatment of lupus nephritis. The company earns income from product sales to healthcare providers and patients, and it may also benefit from potential royalties and milestone payments if it enters into partnerships or collaborations with larger pharmaceutical companies for further development and commercialization of its pipeline products. Additionally, Aurinia may receive funding through research grants or government programs aimed at supporting innovative drug development in the healthcare sector.

Aurinia Pharmaceuticals Financial Statement Overview

Summary

Aurinia Pharmaceuticals is on a positive financial trajectory, marked by strong revenue growth, improved profitability, and effective cash flow management. The solid equity position and conservative leverage enhance financial stability. While past challenges in profitability and cash flow variability are noted, the recent financial performance suggests the company is well-positioned for future growth. Continued attention to capital management and operational efficiency will be key to sustaining this momentum.

Income Statement

Aurinia Pharmaceuticals has demonstrated impressive revenue growth and profitability improvement. The TTM (Trailing-Twelve-Months) data shows a significant increase in total revenue by 10.63% compared to the previous year. Net profit margin improved substantially from the previous negative figures to a positive 23.31%. Both EBIT and EBITDA margins are strong at 20.00% and 30.15%, respectively, reflecting effective cost management and operational efficiency. However, the company previously faced some profitability challenges which are important to monitor.

Balance Sheet

The balance sheet reflects a solid equity position with an equity ratio of 66.70%, indicating financial stability. The debt-to-equity ratio stands at 0.24, suggesting conservative leverage and a manageable debt load. Return on equity has improved to 18.08%, showing enhanced shareholder value creation. However, a reduction in stockholders' equity suggests a need for careful capital management moving forward.

Cash Flow

Aurinia Pharmaceuticals shows strong cash flow management with a notable increase in free cash flow, growing by 109.41% year-over-year. The operating cash flow to net income ratio is 1.53, indicating efficient conversion of earnings into cash. Free cash flow to net income ratio is also robust at 1.52, reflecting the company’s strong cash-generating ability. Nevertheless, past periods show some variability in cash flow performance.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	260.11M	235.13M	175.51M	134.03M	45.60M	50.12M
Gross Profit	232.84M	206.88M	161.37M	128.37M	44.51M	-209.00K
EBITDA	86.50M	31.73M	-63.05M	-103.65M	-177.44M	-102.92M
Net Income	60.64M	5.75M	-78.02M	-108.18M	-180.97M	-102.68M
Balance Sheet
Total Assets	502.56M	550.64M	548.06M	470.86M	543.37M	463.66M
Cash, Cash Equivalents and Short-Term Investments	315.13M	358.48M	350.49M	389.39M	466.08M	398.33M
Total Debt	81.83M	79.37M	97.61M	8.09M	8.74M	8.41M
Total Liabilities	167.26M	173.17M	170.11M	65.42M	64.28M	55.91M
Stockholders Equity	335.30M	377.48M	377.95M	405.44M	479.09M	407.75M
Cash Flow
Free Cash Flow	92.38M	44.11M	-34.18M	-79.82M	-159.19M	-77.20M
Operating Cash Flow	92.66M	44.39M	-33.46M	-79.53M	-157.69M	-69.86M
Investing Cash Flow	46.41M	39.26M	-6.71M	-60.63M	-103.87M	-158.19M
Financing Cash Flow	-119.50M	-49.09M	-5.13M	2.43M	221.11M	194.38M

Aurinia Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 13.17
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AUPH, the sentiment is Positive. The current price of 13.17 is above the 20-day moving average (MA) of 11.79, above the 50-day MA of 12.08, and above the 200-day MA of 9.39, indicating a bullish trend. The MACD of 0.18 indicates Negative momentum. The RSI at 65.98 is Neutral, neither overbought nor oversold. The STOCH value of 71.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AUPH.

Aurinia Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AUPH	―	$1.60B	28.34	17.33%	―	25.59%	―
MNKD	―	$1.72B	51.14	―	―	21.48%	162.30%
IMCR	―	$1.67B	―	-5.38%	―	26.90%	62.72%
SRPT	―	$2.27B	―	-4.76%	―	64.89%	-221.56%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CLDX	―	$1.78B	-8.89	-27.17%	―	-30.25%	-9.70%
BCRX	―	$1.54B	―	―	―	45.85%	76.36%

Aurinia Pharmaceuticals Corporate Events

Aurinia Pharmaceuticals Advances Voclosporin Study in Young Lupus Nephritis Patients

Study Overview: Aurinia Pharmaceuticals is conducting a study titled An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Voclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis. The study aims to evaluate the long-term safety and tolerability of voclosporin over an additional 12 months in young patients who have completed previous treatment for lupus nephritis. This research is significant as it addresses the need for effective long-term treatment options for this condition in younger populations.

Aurinia Pharmaceuticals Advances Lupus Nephritis Study in Young Patients

Study Overview: Aurinia Pharmaceuticals is conducting a study titled A Double-Blind, Placebo-Controlled, Dose Escalation Study to Assess the Efficacy, Safety and Pharmacokinetics of Voclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis. The study aims to evaluate the efficacy and safety of voclosporin in achieving renal response in young patients with active lupus nephritis over 24 weeks, highlighting its potential significance in treating this condition.

Aurinia Pharmaceuticals to Present New LUPKYNIS Data at Key Conferences

Aurinia Pharmaceuticals announced that new data on LUPKYNIS (voclosporin) will be presented at the American College of Rheumatology Convergence and the American Society of Nephrology Kidney Week 2025. These presentations, in collaboration with independent investigators, will highlight real-world effectiveness, usage in pediatric patients, and the drug’s distribution and clearance. The findings aim to enhance the medical community’s understanding of voclosporin’s role in treating lupus nephritis, reinforcing Aurinia’s commitment to advancing patient care.

The most recent analyst rating on (AUPH) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Aurinia Pharmaceuticals stock, see the AUPH Stock Forecast page.

Aurinia Pharmaceuticals Reaffirms Confidence in LUPKYNIS After Retraction

Aurinia Pharmaceuticals responded to a retracted LinkedIn post by an FDA official regarding voclosporin, affirming the positive benefit/risk profile of its product LUPKYNIS. The drug, approved by the FDA in January 2021 and for long-term use in April 2024, has shown sustained efficacy and safety in clinical studies, reinforcing Aurinia’s position in the autoimmune treatment market.

The most recent analyst rating on (AUPH) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Aurinia Pharmaceuticals stock, see the AUPH Stock Forecast page.

Aurinia Pharmaceuticals’ Earnings Call: Strong Growth and Optimism

Aurinia Pharmaceuticals’ recent earnings call paints a picture of robust financial health, marked by significant revenue growth, improved cash flow, and encouraging clinical trial outcomes. While concerns about decreased cash reserves and restructuring costs were noted, the overall sentiment leans towards optimism, driven by the company’s strong performance and increased guidance.

Aurinia Pharmaceuticals Reports Strong Revenue Growth

Aurinia Pharmaceuticals is a biopharmaceutical company dedicated to developing treatments for autoimmune diseases, with a notable product, LUPKYNIS, the first FDA-approved oral therapy for lupus nephritis.